Intech Investment Management LLC decreased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 24.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 220,159 shares of the company’s stock after selling 72,363 shares during the quarter. Johnson & Johnson makes up 0.6% of Intech Investment Management LLC’s holdings, making the stock its 22nd biggest position. Intech Investment Management LLC’s holdings in Johnson & Johnson were worth $58,285,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also modified their holdings of JNJ. National Pension Service grew its stake in Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after acquiring an additional 67,484 shares in the last quarter. IFP Advisors Inc raised its holdings in Johnson & Johnson by 8.8% in the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after acquiring an additional 3,133 shares during the last quarter. Elefante Mark B lifted its stake in Johnson & Johnson by 9.8% in the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after purchasing an additional 2,563 shares in the last quarter. AMG Asset Management Group Inc. lifted its stake in Johnson & Johnson by 172.0% in the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock worth $1,020,000 after purchasing an additional 2,436 shares in the last quarter. Finally, Gradient Investments LLC lifted its stake in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock worth $38,815,000 after purchasing an additional 13,737 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Trading Up 0.0%
JNJ opened at $285.78 on Monday. The business has a fifty day simple moving average of $266.97 and a 200-day simple moving average of $249.85. Johnson & Johnson has a 52 week low of $193.55 and a 52 week high of $288.11. The firm has a market cap of $687.95 billion, a P/E ratio of 43.30, a P/E/G ratio of 2.82 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the previous year, the firm posted $2.80 earnings per share. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson’s payout ratio is 81.21%.
Insider Buying and Selling
In related news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by insiders.
Key Johnson & Johnson News
Investors following JNJ have been watching these news items:
- Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
- Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
- Positive Sentiment: JNJ has risen 10.4% since its latest earnings report, and State Street’s Health Care SPDR added shares on Nov. 10. These reports suggest continued investor interest, though neither guarantees further gains. Johnson & Johnson Up 10.4% Since Last Earnings Report State Street Health Care SPDR Adds Johnson & Johnson
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on JNJ. Bank of America restated a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. UBS Group set a $270.00 price objective on Johnson & Johnson in a research report on Wednesday, October 14th. Royal Bank Of Canada lowered their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 14th. Finally, Johnson Rice lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.
Get Our Latest Research Report on JNJ
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
